{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:43:44Z","timestamp":1792691024231,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Advanced sarcomas remain therapeutically challenging. We evaluated treatment implementation and clinical outcomes after molecular tumor board recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 125 sarcoma patients discussed in our multidisciplinary Molecular and Familial Tumor Board between 2017 and 2023. Clinical benefit was assessed by treatment implementation and by the ratio of progression-free survival on molecularly guided therapy versus the preceding treatment line (PFS2\/PFS1). Overall survival (OS) was measured from first board discussion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 252 pathogenic or likely pathogenic variant records across 133 genes were identified. Molecular profiling enabled therapy recommendations in 71 of 125 patients (56.8%), with treatment implementation in 41 (32.8%). PFS2\/PFS1 evaluation was feasible in 29 patients, and nine (31.0%) had a documented ratio\u2009&gt;\u20091.3. Median PFS2 was 102 days (95% CI 63\u2013233). Two of seven patients (28.6%) receiving poly(ADP-ribose) polymerase (PARP) inhibitor-containing regimens had ratios\u2009&gt;\u20091.3. Median OS in 124 patients was 14.6 months (95% CI 11.7\u201318.5; global log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.220).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Molecular tumor board-guided therapy identified treatment options for selected sarcoma patients. Prolonged disease control in individual PARP-treated cases provides a positive signal that warrants prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06651-1","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:15:15Z","timestamp":1792685715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular tumor board in advanced sarcoma: treatment implementation and clinical outcomes in a real-world cohort"],"prefix":"10.1007","volume":"152","author":[{"given":"Christoph","family":"Weinfurtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Kaupp-Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Gerstenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Niew\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"F\u00fcrstberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Dahlum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambros J.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Mayer-Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinrad","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F. E.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine T.","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wittau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"von Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schulthei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Thaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena I.","family":"Gaidzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"6651_CR1","doi-asserted-by":"publisher","first-page":"13973","DOI":"10.1007\/s00432-023-05179-y","volume":"149","author":"LM Berclaz","year":"2023","unstructured":"Berclaz LM, Burkhard-Meier A, Lange P et al (2023) Implementing precision oncology for sarcoma patients: the CCCLMU molecular tumor board experience. J Cancer Res Clin Oncol 149:13973\u201313983. https:\/\/doi.org\/10.1007\/s00432-023-05179-y","journal-title":"J Cancer Res Clin Oncol"},{"key":"6651_CR2","doi-asserted-by":"publisher","first-page":"1411707","DOI":"10.3389\/fphar.2024.1411707","volume":"15","author":"S Ceddia","year":"2024","unstructured":"Ceddia S, Onesti CE, Vari S et al (2024) Radiological evaluation of response in patients with locally advanced\/metastatic soft tissue sarcoma treated with trabectedin. Front Pharmacol 15:1411707. https:\/\/doi.org\/10.3389\/fphar.2024.1411707","journal-title":"Front Pharmacol"},{"key":"6651_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2","journal-title":"Genome Med"},{"key":"6651_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C (2020) Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov 19:711\u2013736. https:\/\/doi.org\/10.1038\/s41573-020-0076-6","journal-title":"Nat Rev Drug Discov"},{"key":"6651_CR5","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.2174\/092986712802002464","volume":"19","author":"D Davar","year":"2012","unstructured":"Davar D, Beumer JH, Hamieh L, Tawbi H (2012) Role of PARP Inhibitors in Cancer Biology and Therapy. Curr Med Chem 19:3907\u20133921. https:\/\/doi.org\/10.2174\/092986712802002464","journal-title":"Curr Med Chem"},{"key":"6651_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"6651_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA et al (2009) Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N Engl J Med 361:123\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa0900212","journal-title":"N Engl J Med"},{"key":"6651_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00761-023-01392-z","volume":"29","author":"VI Gaidzik","year":"2023","unstructured":"Gaidzik VI, Beer AJ, Thaiss W (2023) Pr\u00e4zisionsmedizin: Bildgebung im molekularen Tumorboard. Die Onkologie 29:1035\u20131042. https:\/\/doi.org\/10.1007\/s00761-023-01392-z","journal-title":"Die Onkologie"},{"key":"6651_CR9","doi-asserted-by":"publisher","unstructured":"Gaidzik VI, Mayer-Steinacker R, Wittau M et al (2024) Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. https:\/\/doi.org\/10.1155\/2024\/5036102. Sarcoma 2024:5036102","DOI":"10.1155\/2024\/5036102"},{"key":"6651_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2013.03.002","volume":"153","author":"LA Garraway","year":"2013","unstructured":"Garraway LA, Lander ES (2013) Lessons from the Cancer Genome. Cell 153:17\u201337. https:\/\/doi.org\/10.1016\/j.cell.2013.03.002","journal-title":"Cell"},{"key":"6651_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41416-024-02868-4","volume":"132","author":"C Gerrand","year":"2025","unstructured":"Gerrand C, Amary F, Anwar HA et al (2025) UK guidelines for the management of bone sarcomas. Br J Cancer 132:32\u201348. https:\/\/doi.org\/10.1038\/s41416-024-02868-4","journal-title":"Br J Cancer"},{"key":"6651_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41698-025-00865-1","volume":"9","author":"BP Gladstone","year":"2025","unstructured":"Gladstone BP, Beha J, Hakariya A et al (2025) Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. NPJ Precis Oncol 9:96. https:\/\/doi.org\/10.1038\/s41698-025-00865-1","journal-title":"NPJ Precis Oncol"},{"key":"6651_CR13","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","volume":"41","author":"MM Gounder","year":"2023","unstructured":"Gounder MM, Bauer TM, Schwartz GK et al (2023) A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol 41:1714\u20131724. https:\/\/doi.org\/10.1200\/JCO.22.01285","journal-title":"J Clin Oncol"},{"key":"6651_CR14","doi-asserted-by":"publisher","first-page":"e11131","DOI":"10.15252\/emmm.201911131","volume":"12","author":"TGP Gr\u00fcnewald","year":"2020","unstructured":"Gr\u00fcnewald TGP, Alonso M, Avnet S et al (2020) Sarcoma treatment in the era of molecular medicine. EMBO Mol Med 12:e11131. https:\/\/doi.org\/10.15252\/emmm.201911131","journal-title":"EMBO Mol Med"},{"key":"6651_CR15","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","volume":"149","author":"K Heinrich","year":"2023","unstructured":"Heinrich K, Miller-Phillips L, Ziemann F et al (2023) Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board. J Cancer Res Clin Oncol 149:1905\u20131915. https:\/\/doi.org\/10.1007\/s00432-022-04165-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"6651_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/ijc.30828","volume":"141","author":"P Horak","year":"2017","unstructured":"Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer 141:877\u2013886. https:\/\/doi.org\/10.1002\/ijc.30828","journal-title":"Int J Cancer"},{"key":"6651_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/2159-8290.CD-21-0126","volume":"11","author":"P Horak","year":"2021","unstructured":"Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discov 11:2780\u20132795. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0126","journal-title":"Cancer Discov"},{"key":"6651_CR18","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.21873\/invivo.13371","volume":"37","author":"T Iwai","year":"2023","unstructured":"Iwai T, Hoshi M, Oebisu N et al (2023) Optimal Prognostic Factors for Metastatic and Inoperable Sarcomas Treated With Pazopanib, Eribulin, and Trabectedin. In Vivo 37:2634\u20132641. https:\/\/doi.org\/10.21873\/invivo.13371","journal-title":"Vivo"},{"key":"6651_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2022)) S3-Leitlinie Adulte Weichgewebesarkome, Langversion 1.1. AWMF-Registernummer: 032\/044OL. Accessed 19 September 2026 https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/adulte-weichgewebesarkome\/"},{"key":"6651_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-019-0388-7","volume":"120","author":"A Napolitano","year":"2019","unstructured":"Napolitano A, Vincenzi B (2019) Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer 120:577\u2013578. https:\/\/doi.org\/10.1038\/s41416-019-0388-7","journal-title":"Br J Cancer"},{"key":"6651_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"6651_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MKB (2013) Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 13:152. https:\/\/doi.org\/10.1186\/1471-2288-13-152","journal-title":"BMC Med Res Methodol"},{"key":"6651_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343\u2013346. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-X","journal-title":"Control Clin Trials"},{"key":"6651_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00432-024-06077-7","volume":"151","author":"C Seeling","year":"2025","unstructured":"Seeling C, Dahlum S, Marienfeld R et al (2025) Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome\u2013 paving the path towards precision medicine: a case report. J Cancer Res Clin Oncol 151:37. https:\/\/doi.org\/10.1007\/s00432-024-06077-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"6651_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-024-01580-3","volume":"17","author":"M Spalato-Ceruso","year":"2024","unstructured":"Spalato-Ceruso M, El Ghazzi N, Italiano A (2024) New strategies in soft tissue sarcoma treatment. J Hematol Oncol 17:76. https:\/\/doi.org\/10.1186\/s13045-024-01580-3","journal-title":"J Hematol Oncol"},{"key":"6651_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network (2017) Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171:950\u2013965.e28. https:\/\/doi.org\/10.1016\/j.cell.2017.10.014","journal-title":"Cell"},{"key":"6651_CR27","doi-asserted-by":"publisher","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","volume":"28","author":"DD Von Hoff","year":"2010","unstructured":"Von Hoff DD, Stephenson JJ, Rosen P et al (2010) Pilot Study Using Molecular Profiling of Patients\u2019 Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. J Clin Oncol 28:4877\u20134883. https:\/\/doi.org\/10.1200\/JCO.2009.26.5983","journal-title":"J Clin Oncol"},{"key":"6651_CR28","doi-asserted-by":"publisher","first-page":"oyae271","DOI":"10.1093\/oncolo\/oyae271","volume":"30","author":"A Wahida","year":"2025","unstructured":"Wahida A, Kurzrock R (2025) The Molecular Tumor Board Turns 10: The Age of Complexity. Oncologist 30:oyae271. https:\/\/doi.org\/10.1093\/oncolo\/oyae271","journal-title":"Oncologist"},{"key":"6651_CR29","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164. https:\/\/doi.org\/10.1093\/nar\/gkq603","journal-title":"Nucleic Acids Res"},{"key":"6651_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41416-024-02721-8","volume":"131","author":"JA Watkins","year":"2024","unstructured":"Watkins JA, Trotman J, Tadross JA et al (2024) Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma. Br J Cancer 131:860\u2013869. https:\/\/doi.org\/10.1038\/s41416-024-02721-8","journal-title":"Br J Cancer"},{"key":"6651_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association (2025) World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA 333:71\u201374. https:\/\/doi.org\/10.1001\/jama.2024.21972","journal-title":"JAMA"},{"key":"6651_CR32","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1724600820925095","volume":"35","author":"LB Xu","year":"2020","unstructured":"Xu LB, Zhao ZG, Xu SF et al (2020) The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. Int J Biol Markers 35:14\u201322. https:\/\/doi.org\/10.1177\/1724600820925095","journal-title":"Int J Biol Markers"},{"key":"6651_CR33","doi-asserted-by":"publisher","first-page":"946022","DOI":"10.3389\/fonc.2022.946022","volume":"12","author":"Z Zou","year":"2022","unstructured":"Zou Z, Sun W, Xu Y et al (2022) Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets. Front Oncol 12:946022. https:\/\/doi.org\/10.3389\/fonc.2022.946022","journal-title":"Front Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06651-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:26:27Z","timestamp":1792689987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06651-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6651"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06651-1","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interest.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by the local ethics committee of the University of Ulm (reference 463\/21 and reference 327\/23) and follows the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Institutional Review Board Statement:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient data were collected in the context of clinical care; every patient gave consent to the specific therapy. Written informed consent has been obtained from the patient(s) to publish this paper.","order":3,"name":"Ethics","label":"Informed Consent Statement:","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, ChatGPT (OpenAI) and the AI-based editor in Microsoft Word were used to support language and editorial revision and to assist with data analysis and the preparation of tables and figures. All outputs were reviewed and edited by the authors, who take full responsibility for the final content of the manuscript.","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"201"}}